The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: Data from the randomised SBG 2000-1 study
Mikkel Rosendahl(Rigshospitalet), Michael Andersson(University of Copenhagen), Henrik Lindman(Uppsala University), Jonas Bergh(Karolinska Institutet), Elisabet Lidbrink(Stockholm South General Hospital), Carl Blomquist, Henning T. Mouridsen(Danish Breast Cancer Cooperative Group), Johan Ahlgren(Gävle Hospital), Jørn Andersen(Aarhus University Hospital), Karsten Bjerre(Danish Breast Cancer Cooperative Group)
Cited by 21
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k